1
|
Kojima N, Taylor CA, Tenforde MW, Ujamaa D, O’Halloran A, Patel K, Chai SJ, Daily Kirley P, Alden NB, Kawasaki B, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Reeg L, Tellez Nunez V, Lynfield R, Como-Sabetti K, Ropp SL, Shaw YP, Spina NL, Barney G, Bushey S, Popham K, Moran NE, Shiltz E, Sutton M, Abdullah N, Talbot HK, Schaffner W, Chatelain R, Price A, Garg S, Havers FP, Bozio CH. Clinical Outcomes of US Adults Hospitalized for COVID-19 and Influenza in the Respiratory Virus Hospitalization Surveillance Network, October 2021-September 2022. Open Forum Infect Dis 2024; 11:ofad702. [PMID: 38269052 PMCID: PMC10807992 DOI: 10.1093/ofid/ofad702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Accepted: 12/28/2023] [Indexed: 01/26/2024] Open
Abstract
Severe outcomes were common among adults hospitalized for COVID-19 or influenza, while the percentage of COVID-19 hospitalizations involving critical care decreased from October 2021 to September 2022. During the Omicron BA.5 period, intensive care unit admission frequency was similar for COVID-19 and influenza, although patients with COVID-19 had a higher frequency of in-hospital death.
Collapse
Affiliation(s)
- Noah Kojima
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Christopher A Taylor
- Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Mark W Tenforde
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Dawud Ujamaa
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Alissa O’Halloran
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Kadam Patel
- Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Shua J Chai
- California Emerging Infections Program, Oakland, California, USA
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Pam Daily Kirley
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Nisha B Alden
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Breanna Kawasaki
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - James Meek
- Connecticut Emerging Infections Program, New Haven, Connecticut, USA
- Yale School of Public Health, New Haven, Connecticut, USA
| | | | - Evan J Anderson
- School of Medicine, Emory University, Atlanta, Georgia, USA
- Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, Georgia, USA
- Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA
| | - Kyle P Openo
- School of Medicine, Emory University, Atlanta, Georgia, USA
- Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, Georgia, USA
- Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA
| | - Libby Reeg
- Michigan Department of Health and Human Services, Lansing, Michigan, USA
| | - Val Tellez Nunez
- Michigan Department of Health and Human Services, Lansing, Michigan, USA
| | - Ruth Lynfield
- Minnesota Department of Health, Saint Paul, Minnesota, USA
| | | | - Susan L Ropp
- New Mexico Department of Health, Albuquerque, New Mexico, USA
| | - Yomei P Shaw
- New Mexico Department of Health, Albuquerque, New Mexico, USA
| | - Nancy L Spina
- New York State Department of Health, Albany, New York, USA
| | - Grant Barney
- New York State Department of Health, Albany, New York, USA
| | - Sophrena Bushey
- School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA
| | - Kevin Popham
- School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA
| | | | - Eli Shiltz
- Ohio Department of Health, Columbus, Ohio, USA
| | - Melissa Sutton
- Public Health Division, Oregon Health Authority, Portland, Oregon, USA
| | - Nasreen Abdullah
- Public Health Division, Oregon Health Authority, Portland, Oregon, USA
| | - H Keipp Talbot
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | - Ryan Chatelain
- Salt Lake County Health Department, Salt Lake City, Utah, USA
| | - Andrea Price
- Salt Lake County Health Department, Salt Lake City, Utah, USA
| | - Shikha Garg
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Fiona P Havers
- Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Catherine H Bozio
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
2
|
Famati EA, Ujamaa D, O’Halloran A, Kirley PD, Chai SJ, Armistead I, Alden NB, Yousey-Hindes K, Openo KP, Ryan PA, Monroe ML, Falkowski A, Kim S, Lynfield R, McMahon M, Angeles KM, Khanlian SA, Spina NL, Bennett NM, Gaitán MA, Shiltz E, Lung K, Thomas A, Talbot HK, Schaffner W, George A, Staten H, Bozio CH, Garg S. Association of Chronic Medical Conditions With Severe Outcomes Among Nonpregnant Adults 18-49 Years Old Hospitalized With Influenza, FluSurv-NET, 2011-2019. Open Forum Infect Dis 2023; 10:ofad599. [PMID: 38130595 PMCID: PMC10733180 DOI: 10.1093/ofid/ofad599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 11/27/2023] [Indexed: 12/23/2023] Open
Abstract
Background Older age and chronic conditions are associated with severe influenza outcomes; however, data are only comprehensively available for adults ≥65 years old. Using data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), we identified characteristics associated with severe outcomes in adults 18-49 years old hospitalized with influenza. Methods We included FluSurv-NET data from nonpregnant adults 18-49 years old hospitalized with laboratory-confirmed influenza during the 2011-2012 through 2018-2019 seasons. We used bivariate and multivariable logistic regression to determine associations between select characteristics and severe outcomes including intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and in-hospital death. Results A total of 16 140 patients aged 18-49 years and hospitalized with influenza were included in the analysis; the median age was 39 years, and 26% received current-season influenza vaccine before hospitalization. Obesity, asthma, and diabetes mellitus were the most common chronic conditions. Conditions associated with a significantly increased risk of severe outcomes included age group 30-39 or 40-49 years (IMV, age group 30-39 years: adjusted odds ratio [aOR], 1.25; IMV, age group 40-49 years: aOR, 1.36; death, age group 30-39 years: aOR, 1.28; death, age group 40-49 years: aOR, 1.69), being unvaccinated (ICU: aOR, 1.18; IMV: aOR, 1.25; death: aOR, 1.48), and having chronic conditions including extreme obesity and chronic lung, cardiovascular, metabolic, neurologic, or liver diseases (ICU: range aOR, 1.22-1.56; IMV: range aOR, 1.17-1.54; death: range aOR, 1.43-2.36). Conclusions To reduce the morbidity and mortality associated with influenza among adults aged 18-49 years, health care providers should strongly encourage receipt of annual influenza vaccine and lifestyle/behavioral modifications, particularly among those with chronic medical conditions.
Collapse
Affiliation(s)
- Efemona A Famati
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Dawud Ujamaa
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- General Dynamics Information Technology, Falls Church, Virginia, USA
| | - Alissa O’Halloran
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Pam Daily Kirley
- California Emerging Infections Program, Oakland, California, USA
| | - Shua J Chai
- California Emerging Infections Program, Oakland, California, USA
- Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Isaac Armistead
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Nisha B Alden
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Kimberly Yousey-Hindes
- Emerging Infections Program, Yale University School of Public Health, New Haven, Connecticut, USA
| | - Kyle P Openo
- Georgia Emerging Infections Program, Atlanta, Georgia, USA
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA
- Emory University School of Medicine, Atlanta, Georgia, USA
| | | | - Maya L Monroe
- Maryland Department of Health, Baltimore, Maryland, USA
| | - Anna Falkowski
- Michigan Department of Health and Human Services, Lansing, Michigan, USA
| | - Sue Kim
- Michigan Department of Health and Human Services, Lansing, Michigan, USA
| | - Ruth Lynfield
- Minnesota Department of Health, St.Paul, Minnesota, USA
| | | | - Kathy M Angeles
- New Mexico Emerging Infections Program, Albuquerque, New Mexico, USA
| | - Sarah A Khanlian
- New Mexico Emerging Infections Program, Albuquerque, New Mexico, USA
| | - Nancy L Spina
- NewYork State Department of Health, Albany, New York, USA
| | - Nancy M Bennett
- University of Rochester School of Medicine and Dentistry, Rochester, NewYork, USA
| | - Maria A Gaitán
- University of Rochester School of Medicine and Dentistry, Rochester, NewYork, USA
| | - Eli Shiltz
- Ohio Department of Health, Columbus, Ohio, USA
| | - Krista Lung
- Ohio Department of Health, Columbus, Ohio, USA
| | - Ann Thomas
- Oregon Health Authority, Portland, Oregon, USA
| | - H Keipp Talbot
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | | | - Andrea George
- Salt Lake County Health Department, Salt Lake City, Utah, USA
| | - Holly Staten
- Salt Lake County Health Department, Salt Lake City, Utah, USA
| | - Catherine H Bozio
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Shikha Garg
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
3
|
Sumner KM, Masalovich S, O'Halloran A, Holstein R, Reingold A, Kirley PD, Alden NB, Herlihy RK, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Monroe ML, Leegwater L, Henderson J, Lynfield R, McMahon M, McMullen C, Angeles KM, Spina NL, Engesser K, Bennett NM, Felsen CB, Lung K, Shiltz E, Thomas A, Talbot HK, Schaffner W, Swain A, George A, Rolfes MA, Reed C, Garg S. Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010-19: a repeated cross-sectional study. Lancet Microbe 2023; 4:e903-e912. [PMID: 37769676 PMCID: PMC10872935 DOI: 10.1016/s2666-5247(23)00187-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 06/12/2023] [Accepted: 06/13/2023] [Indexed: 10/03/2023]
Abstract
BACKGROUND Influenza burden varies across seasons, partly due to differences in circulating influenza virus types or subtypes. Using data from the US population-based surveillance system, Influenza Hospitalization Surveillance Network (FluSurv-NET), we aimed to assess the severity of influenza-associated outcomes in individuals hospitalised with laboratory-confirmed influenza virus infections during the 2010-11 to 2018-19 influenza seasons. METHODS To evaluate the association between influenza virus type or subtype causing the infection (influenza A H3N2, A H1N1pdm09, and B viruses) and in-hospital severity outcomes (intensive care unit [ICU] admission, use of mechanical ventilation or extracorporeal membrane oxygenation [ECMO], and death), we used FluSurv-NET to capture data for laboratory-confirmed influenza-associated hospitalisations from the 2010-11 to 2018-19 influenza seasons for individuals of all ages living in select counties in 13 US states. All individuals had to have an influenza virus test within 14 days before or during their hospital stay and an admission date between Oct 1 and April 30 of an influenza season. Exclusion criteria were individuals who did not have a complete chart review; cases from sites that contributed data for three or fewer seasons; hospital-onset cases; cases with unidentified influenza type; cases of multiple influenza virus type or subtype co-infection; or individuals younger than 6 months and ineligible for the influenza vaccine. Logistic regression models adjusted for influenza season, influenza vaccination status, age, and FluSurv-NET site compared odds of in-hospital severity by virus type or subtype. When missing, influenza A subtypes were imputed using chained equations of known subtypes by season. FINDINGS Data for 122 941 individuals hospitalised with influenza were captured in FluSurv-NET from the 2010-11 to 2018-19 seasons; after exclusions were applied, 107 941 individuals remained and underwent influenza A virus imputation when missing A subtype (43·4%). After imputation, data for 104 969 remained and were included in the final analytic sample. Averaging across imputed datasets, 57·7% (weighted percentage) had influenza A H3N2, 24·6% had influenza A H1N1pdm09, and 17·7% had influenza B virus infections; 16·7% required ICU admission, 6·5% received mechanical ventilation or ECMO, and 3·0% died (95% CIs had a range of less than 0·1% and are not displayed). Individuals with A H1N1pdm09 had higher odds of in-hospital severe outcomes than those with A H3N2: adjusted odds ratios (ORs) for A H1N1pdm09 versus A H3N2 were 1·42 (95% CI 1·32-1·52) for ICU admission; 1·79 (1·60-2·00) for mechanical ventilation or ECMO use; and 1·25 (1·07-1·46) for death. The adjusted ORs for individuals infected with influenza B versus influenza A H3N2 were 1·06 (95% CI 1·01-1·12) for ICU admission, 1·14 (1·05-1·24) for mechanical ventilation or ECMO use, and 1·18 (1·07-1·31) for death. INTERPRETATION Despite a higher burden of hospitalisations with influenza A H3N2, we found an increased likelihood of in-hospital severe outcomes in individuals hospitalised with influenza A H1N1pdm09 or influenza B virus. Thus, it is important for individuals to receive an annual influenza vaccine and for health-care providers to provide early antiviral treatment for patients with suspected influenza who are at increased risk of severe outcomes, not only when there is high influenza A H3N2 virus circulation but also when influenza A H1N1pdm09 and influenza B viruses are circulating. FUNDING The US Centers for Disease Control and Prevention.
Collapse
Affiliation(s)
- Kelsey M Sumner
- Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
| | - Svetlana Masalovich
- Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Alissa O'Halloran
- Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Rachel Holstein
- Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Arthur Reingold
- School of Public Health, University of California Berkeley, Berkeley, CA, USA
| | | | - Nisha B Alden
- Colorado Department of Public Health and Environment, Denver, CA, USA
| | - Rachel K Herlihy
- Colorado Department of Public Health and Environment, Denver, CA, USA
| | - James Meek
- Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, USA
| | - Kimberly Yousey-Hindes
- Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, USA
| | - Evan J Anderson
- Department of Medicine and Depatment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA, USA; Veterans Affairs Medical Center, Atlanta, GA, USA
| | - Kyle P Openo
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA, USA; Veterans Affairs Medical Center, Atlanta, GA, USA
| | | | - Lauren Leegwater
- Michigan Department of Health and Human Services, Lansing, MI, USA
| | - Justin Henderson
- Michigan Department of Health and Human Services, Lansing, MI, USA
| | | | | | | | - Kathy M Angeles
- New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, NM, USA
| | - Nancy L Spina
- New York State Department of Health, Albany, NY, USA
| | | | - Nancy M Bennett
- University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Christina B Felsen
- University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Krista Lung
- Ohio Department of Health, Columbus, OH, USA
| | - Eli Shiltz
- Ohio Department of Health, Columbus, OH, USA
| | | | - H Keipp Talbot
- Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - Ashley Swain
- Salt Lake County Health Department, Salt Lake City, UT, USA
| | - Andrea George
- Salt Lake County Health Department, Salt Lake City, UT, USA
| | - Melissa A Rolfes
- Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Carrie Reed
- Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Shikha Garg
- Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|
4
|
Shah MM, Patel K, Milucky J, Taylor CA, Reingold A, Armistead I, Meek J, Anderson EJ, Weigel A, Reeg L, Como‐Sabetti K, Ropp SL, Muse A, Bushey S, Shiltz E, Sutton M, Talbot HK, Chatelain R, Havers FP. Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022. Influenza Other Respir Viruses 2023; 17:e13107. [PMID: 36875205 PMCID: PMC9981874 DOI: 10.1111/irv.13107] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 01/26/2023] [Accepted: 01/27/2023] [Indexed: 03/06/2023] Open
Abstract
Background Bacterial and viral infections can occur with SARS-CoV-2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood. Methods We used the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system, to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory-confirmed SARS-CoV-2 infection between March 2020 and April 2022. Clinician-driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. We also describe the prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non-SARS-CoV-2 endemic coronaviruses. Results Among 36 490 hospitalized adults with COVID-19, 53.3% had bacterial cultures taken within 7 days of admission and 6.0% of these had a clinically relevant bacterial pathogen. After adjustment for demographic factors and co-morbidities, bacterial infections in patients with COVID-19 within 7 days of admission were associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing. Staphylococcus aureus and Gram-negative rods were the most frequently isolated bacterial pathogens. Among hospitalized adults with COVID-19, 2766 (7.6%) were tested for seven virus groups. A non-SARS-CoV-2 virus was identified in 0.9% of tested patients. Conclusions Among patients with clinician-driven testing, 6.0% of adults hospitalized with COVID-19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections; identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.
Collapse
Affiliation(s)
- Melisa M. Shah
- Epidemic Intelligence ServiceCenters for Disease Control and PreventionAtlantaGeorgiaUSA
- COVID‐19 Emergency Response TeamCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | - Kadam Patel
- COVID‐19 Emergency Response TeamCenters for Disease Control and PreventionAtlantaGeorgiaUSA
- General Dynamics Information TechnologyAtlantaGeorgiaUSA
- Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory DiseasesCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | - Jennifer Milucky
- COVID‐19 Emergency Response TeamCenters for Disease Control and PreventionAtlantaGeorgiaUSA
- Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory DiseasesCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | - Christopher A. Taylor
- COVID‐19 Emergency Response TeamCenters for Disease Control and PreventionAtlantaGeorgiaUSA
- Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory DiseasesCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | - Arthur Reingold
- California Emerging Infections ProgramOaklandCaliforniaUSA
- University of California, BerkelyBerkelyCaliforniaUSA
| | - Isaac Armistead
- Colorado Department of Public Health & EnvironmentDenverColoradoUSA
| | - James Meek
- Connecticut Emerging Infections ProgramYale School of Public HealthNew HavenConnecticutUSA
| | - Evan J. Anderson
- Departments of Medicine and PediatricsEmory University School of MedicineAtlantaGeorgiaUSA
- Georgia Emerging Infections Program, Georgia Department of Public HealthAtlanta Veterans Affairs Medical CenterAtlantaGeorgiaUSA
| | | | - Libby Reeg
- Michigan Department of Health and Human ServicesLansingMichiganUSA
| | | | - Susan L. Ropp
- New Mexico Department of HealthSanta FeNew MexicoUSA
| | - Alison Muse
- New York State Department of HealthAlbanyNew YorkUSA
| | - Sophrena Bushey
- University of Rochester School of Medicine and DentistryRochesterNew YorkUSA
| | - Eli Shiltz
- Ohio Department of HealthColumbusOhioUSA
| | - Melissa Sutton
- Public Health DivisionOregon Health AuthorityPortlandOregonUSA
| | | | | | - Fiona P. Havers
- COVID‐19 Emergency Response TeamCenters for Disease Control and PreventionAtlantaGeorgiaUSA
- Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory DiseasesCenters for Disease Control and PreventionAtlantaGeorgiaUSA
- US Public Health Service Commissioned CorpsRockvilleMarylandUSA
| | | |
Collapse
|
5
|
Delahoy MJ, Ujamaa D, Taylor CA, Cummings C, Anglin O, Holstein R, Milucky J, O’Halloran A, Patel K, Pham H, Whitaker M, Reingold A, Chai SJ, Alden NB, Kawasaki B, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Weigel A, Teno K, Reeg L, Leegwater L, Lynfield R, McMahon M, Ropp S, Rudin D, Muse A, Spina N, Bennett NM, Popham K, Billing LM, Shiltz E, Sutton M, Thomas A, Schaffner W, Talbot HK, Crossland MT, McCaffrey K, Hall AJ, Burns E, McMorrow M, Reed C, Havers FP, Garg S. Comparison of Influenza and Coronavirus Disease 2019-Associated Hospitalizations Among Children Younger Than 18 Years Old in the United States: FluSurv-NET (October-April 2017-2021) and COVID-NET (October 2020-September 2021). Clin Infect Dis 2023; 76:e450-e459. [PMID: 35594564 PMCID: PMC9129156 DOI: 10.1093/cid/ciac388] [Citation(s) in RCA: 21] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 05/04/2022] [Accepted: 05/13/2022] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Influenza virus and SARS-CoV-2 are significant causes of respiratory illness in children. METHODS Influenza- and COVID-19-associated hospitalizations among children <18 years old were analyzed from FluSurv-NET and COVID-NET, 2 population-based surveillance systems with similar catchment areas and methodology. The annual COVID-19-associated hospitalization rate per 100 000 during the ongoing COVID-19 pandemic (1 October 2020-30 September 2021) was compared with influenza-associated hospitalization rates during the 2017-2018 through 2019-2020 influenza seasons. In-hospital outcomes, including intensive care unit (ICU) admission and death, were compared. RESULTS Among children <18 years, the COVID-19-associated hospitalization rate (48.2) was higher than influenza-associated hospitalization rates: 2017-2018 (33.5), 2018-2019 (33.8), and 2019-2020 (41.7). The COVID-19-associated hospitalization rate was higher among adolescents 12-17 years old (COVID-19: 59.9; influenza range: 12.2-14.1), but similar or lower among children 5-11 (COVID-19: 25.0; influenza range: 24.3-31.7) and 0-4 (COVID-19: 66.8; influenza range: 70.9-91.5) years old. Among children <18 years, a higher proportion with COVID-19 required ICU admission compared with influenza (26.4% vs 21.6%; P < .01). Pediatric deaths were uncommon during both COVID-19- and influenza-associated hospitalizations (0.7% vs 0.5%; P = .28). CONCLUSIONS In the setting of extensive mitigation measures during the COVID-19 pandemic, the annual COVID-19-associated hospitalization rate during 2020-2021 was higher among adolescents and similar or lower among children <12 years compared with influenza during the 3 seasons before the COVID-19 pandemic. COVID-19 adds substantially to the existing burden of pediatric hospitalizations and severe outcomes caused by influenza and other respiratory viruses.
Collapse
Affiliation(s)
- Miranda J. Delahoy
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Corresponding author: Miranda J. Delahoy, Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd. MS H24-7, Atlanta, Georgia 30329, United States;
| | - Dawud Ujamaa
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Christopher A. Taylor
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Charisse Cummings
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Onika Anglin
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Rachel Holstein
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Jennifer Milucky
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Alissa O’Halloran
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Kadam Patel
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Huong Pham
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Michael Whitaker
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Arthur Reingold
- California Emerging Infections Program, Oakland, California, United States
- University of California, Berkeley School of Public Health, Berkeley, California, United States
| | - Shua J. Chai
- California Emerging Infections Program, Oakland, California, United States
- Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Nisha B. Alden
- Colorado Department of Public Health and Environment, Denver, Colorado, United States
| | - Breanna Kawasaki
- Colorado Department of Public Health and Environment, Denver, Colorado, United States
| | - James Meek
- Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, United States
| | - Kimberly Yousey-Hindes
- Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, United States
| | - Evan J. Anderson
- Emory University School of Medicine, Atlanta, Georgia, United States
- Georgia Emerging Infections Program, Georgia Department of Health, Atlanta, Georgia, United States
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States
| | - Kyle P. Openo
- Emory University School of Medicine, Atlanta, Georgia, United States
- Georgia Emerging Infections Program, Georgia Department of Health, Atlanta, Georgia, United States
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States
| | - Andy Weigel
- Iowa Department of Health, Des Moines, Iowa, United States
| | - Kenzie Teno
- Iowa Department of Health, Des Moines, Iowa, United States
| | - Libby Reeg
- Michigan Department of Health and Human Services, Lansing, Michigan, United States
| | - Lauren Leegwater
- Michigan Department of Health and Human Services, Lansing, Michigan, United States
| | - Ruth Lynfield
- Minnesota Department of Health, Saint Paul, Minnesota, United States
| | - Melissa McMahon
- Minnesota Department of Health, Saint Paul, Minnesota, United States
| | - Susan Ropp
- New Mexico Emerging Infections Program, New Mexico Department of Health, Santa Fe, New Mexico, United States
| | - Dominic Rudin
- New Mexico Emerging Infections Program, New Mexico Department of Health, Santa Fe, New Mexico, United States
| | - Alison Muse
- New York State Department of Health, Albany, New York, United States
| | - Nancy Spina
- New York State Department of Health, Albany, New York, United States
| | - Nancy M. Bennett
- University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
| | - Kevin Popham
- Rochester Emerging Infections Program, University of Rochester Medical Center, Rochester, New York, United States
| | | | - Eli Shiltz
- Ohio Department of Health, Columbus, Ohio, United States
| | - Melissa Sutton
- Public Health Division, Oregon Health Authority, Salem, Oregon, United States
| | - Ann Thomas
- Public Health Division, Oregon Health Authority, Salem, Oregon, United States
| | - William Schaffner
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
| | - H. Keipp Talbot
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
| | | | | | - Aron J. Hall
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Erin Burns
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Meredith McMorrow
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Carrie Reed
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Fiona P. Havers
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Shikha Garg
- CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Alternative corresponding authors: Shikha Garg, Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd. MS H24-7, Atlanta, Georgia 30329, United States;
| |
Collapse
|
6
|
Tenforde MW, Cummings CN, O’Halloran AC, Rothrock G, Kirley PD, Alden NB, Meek J, Yousey-Hindes K, Openo KP, Anderson EJ, Monroe ML, Kim S, Nunez VT, McMahon M, McMullen C, Khanlian SA, Spina NL, Muse A, Gaitán MA, Felsen CB, Lung K, Shiltz E, Sutton M, Thomas A, Talbot HK, Schaffner W, Price A, Chatelain R, Reed C, Garg S. Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019. Open Forum Infect Dis 2023; 10:ofac681. [PMID: 36686630 PMCID: PMC9846184 DOI: 10.1093/ofid/ofac681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Accepted: 12/15/2022] [Indexed: 12/23/2022] Open
Abstract
From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015-2016 through 2018-2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.
Collapse
Affiliation(s)
- Mark W Tenforde
- Correspondence: Mark W. Tenforde, MD, PhD, MPH, DTM&H, 1600 Clifton Road NE, Mailstop H24-7, Atlanta, GA 30329-4027 ()
| | - Charisse N Cummings
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Alissa C O’Halloran
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | - Pam Daily Kirley
- California Emerging Infections Program, Oakland, California, USA
| | - Nisha B Alden
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - James Meek
- Connecticut Emerging Infections Program, New Haven, Connecticut, USA
- Yale School of Public Health, New Haven, Connecticut, USA
| | - Kimberly Yousey-Hindes
- Connecticut Emerging Infections Program, New Haven, Connecticut, USA
- Yale School of Public Health, New Haven, Connecticut, USA
| | - Kyle P Openo
- Georgia Emerging Infections Program, Atlanta, Georgia, USA
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA
- Emory University School of Medicine, Atlanta, Georgia, USA
| | - Evan J Anderson
- Georgia Emerging Infections Program, Atlanta, Georgia, USA
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA
- Emory University School of Medicine, Atlanta, Georgia, USA
| | - Maya L Monroe
- Maryland Department of Health, Baltimore, Maryland, USA
| | - Sue Kim
- Michigan Department of Health and Human Services, Lansing, Michigan, USA
| | - Val Tellez Nunez
- Michigan Department of Health and Human Services, Lansing, Michigan, USA
| | | | | | - Sarah A Khanlian
- University of New Mexico Health Science Center, Santa Fe, New Mexico, USA
| | - Nancy L Spina
- New York State Department of Health, Albany, New York, USA
| | - Alison Muse
- New York State Department of Health, Albany, New York, USA
| | - Maria A Gaitán
- University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
| | - Christina B Felsen
- University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
| | - Krista Lung
- Ohio Department of Health, Columbus, Ohio, USA
| | - Eli Shiltz
- Ohio Department of Health, Columbus, Ohio, USA
| | | | - Ann Thomas
- Oregon Health Authority, Portland, Oregon, USA
| | - H Keipp Talbot
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | | | - Andrea Price
- Salt Lake County Health Department, Salt Lake City, Utah, USA
| | - Ryan Chatelain
- Salt Lake County Health Department, Salt Lake City, Utah, USA
| | - Carrie Reed
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | |
Collapse
|
7
|
Parisi CE, Yousey‐Hindes K, Holstein R, O'Halloran A, Kirley PD, Alden NB, Anderson EJ, Kim S, McMahon M, Khanlian SA, Spina N, Gaitan MA, Shiltz E, Thomas A, Schaffner W, Talbot K, Crossland MT, Cook RL, Garg S, Meek J, Hadler J. Drug use and severe outcomes among adults hospitalized with influenza, 2016-2019. Influenza Other Respir Viruses 2023; 17:e13052. [PMID: 36300969 PMCID: PMC9835414 DOI: 10.1111/irv.13052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Revised: 08/25/2022] [Accepted: 08/26/2022] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND Influenza is a persistent public health problem associated with severe morbidity and mortality. Drug use is related to myriad health complications, but the relationship between drug use and severe influenza outcomes is not well understood. The study objective was to evaluate the relationship between drug use and severe influenza-associated outcomes. METHODS Data were collected by the Influenza Hospitalization Surveillance Network (FluSurv-NET) from the 2016-2017 through 2018-2019 influenza seasons. Among persons hospitalized with influenza, descriptive statistics and logistic regression models were used to analyze differences in demographic characteristics, risk and behavioral factors, and severe outcomes (intensive care unit [ICU] admission, mechanical ventilation, or death) between people who use drugs (PWUD), defined as having documented drug use within the past year, and non-PWUD. RESULTS Among 48,430 eligible hospitalized influenza cases, 2019 were PWUD and 46,411 were non-PWUD. PWUD were younger than non-PWUD and more likely to be male, non-Hispanic Black or Hispanic/Latino, smoke tobacco, abuse alcohol, and have chronic conditions including asthma, chronic liver disease, chronic lung disease, or immunosuppressive conditions. PWUD had greater odds of ICU admission and mechanical ventilation, but not death compared with non-PWUD; however, these findings were not statistically significant after adjustment. Opioid use specifically was associated with increased risk of ICU admission and mechanical ventilation. CONCLUSION These results support targeted initiatives to prevent influenza in this population, including influenza vaccination, which remains one of the most important tools to prevent influenza infection and associated severe outcomes.
Collapse
Affiliation(s)
- Christina E. Parisi
- Department of EpidemiologyUniversity of FloridaGainesvilleFloridaUSA
- Emerging Infections ProgramYale University School of Public HealthNew HavenConnecticutUSA
| | - Kimberly Yousey‐Hindes
- Emerging Infections ProgramYale University School of Public HealthNew HavenConnecticutUSA
| | - Rachel Holstein
- Influenza DivisionCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | - Alissa O'Halloran
- Influenza DivisionCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | | | - Nisha B. Alden
- Colorado Department of Public Health and EnvironmentDenverColoradoUSA
| | - Evan J. Anderson
- Emory University School of MedicineAtlantaGeorgiaUSA
- Georgia Emerging Infections ProgramAtlantaGeorgiaUSA
- Atlanta VA Medical CenterDecaturGeorgiaUSA
| | - Sue Kim
- Michigan Department of Health and Human ServicesLansingMichiganUSA
| | | | | | - Nancy Spina
- New York State Department of HealthAlbanyNew YorkUSA
| | - Maria A. Gaitan
- Center for Community Health and PreventionUniversity of Rochester School of Medicine and DentistryRochesterNew YorkUSA
| | - Eli Shiltz
- Ohio Department of HealthColumbusOhioUSA
| | - Ann Thomas
- Oregon Health AuthorityPortlandOregonUSA
| | | | - Keipp Talbot
- Vanderbilt University School of MedicineNashvilleTennesseeUSA
| | | | - Robert L. Cook
- Department of EpidemiologyUniversity of FloridaGainesvilleFloridaUSA
| | - Shikha Garg
- Influenza DivisionCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | - James Meek
- Emerging Infections ProgramYale University School of Public HealthNew HavenConnecticutUSA
| | - James Hadler
- Emerging Infections ProgramYale University School of Public HealthNew HavenConnecticutUSA
| |
Collapse
|
8
|
Adams K, Tastad KJ, Huang S, Ujamaa D, Kniss K, Cummings C, Reingold A, Roland J, Austin E, Kawasaki B, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Reeg L, Leegwater L, McMahon M, Bye E, Poblete M, Landis Z, Spina NL, Engesser K, Bennett NM, Gaitan MA, Shiltz E, Moran N, Sutton M, Abdullah N, Schaffner W, Talbot HK, Olsen K, Staten H, Taylor CA, Havers FP, Reed C, Budd A, Garg S, O’Halloran A, Brammer L. Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza - United States, 2021-22 Influenza Season. MMWR Morb Mortal Wkly Rep 2022; 71:1589-1596. [PMID: 36520656 PMCID: PMC9762905 DOI: 10.15585/mmwr.mm7150a4] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The 2022-23 influenza season shows an early rise in pediatric influenza-associated hospitalizations (1). SARS-CoV-2 viruses also continue to circulate (2). The current influenza season is the first with substantial co-circulation of influenza viruses and SARS-CoV-2 (3). Although both seasonal influenza viruses and SARS-CoV-2 can contribute to substantial pediatric morbidity (3-5), whether coinfection increases disease severity compared with that associated with infection with one virus alone is unknown. This report describes characteristics and prevalence of laboratory-confirmed influenza virus and SARS-CoV-2 coinfections among patients aged <18 years who had been hospitalized or died with influenza as reported to three CDC surveillance platforms during the 2021-22 influenza season. Data from two Respiratory Virus Hospitalizations Surveillance Network (RESP-NET) platforms (October 1, 2021-April 30, 2022),§ and notifiable pediatric deaths associated¶ with influenza virus and SARS-CoV-2 coinfection (October 3, 2021-October 1, 2022)** were analyzed. SARS-CoV-2 coinfections occurred in 6% (32 of 575) of pediatric influenza-associated hospitalizations and in 16% (seven of 44) of pediatric influenza-associated deaths. Compared with patients without coinfection, a higher proportion of those hospitalized with coinfection received invasive mechanical ventilation (4% versus 13%; p = 0.03) and bilevel positive airway pressure or continuous positive airway pressure (BiPAP/CPAP) (6% versus 16%; p = 0.05). Among seven coinfected patients who died, none had completed influenza vaccination, and only one received influenza antivirals.†† To help prevent severe outcomes, clinicians should follow recommended respiratory virus testing algorithms to guide treatment decisions and consider early antiviral treatment initiation for pediatric patients with suspected or confirmed influenza, including those with SARS-CoV-2 coinfection who are hospitalized or at increased risk for severe illness. The public and parents should adopt prevention strategies including considering wearing well-fitted, high-quality masks when respiratory virus circulation is high and staying up-to-date with recommended influenza and COVID-19 vaccinations for persons aged ≥6 months.
Collapse
|
9
|
Melisa S, Taylor C, Patel K, Milucky J, Whitaker M, Pham H, Anglin O, Reingold A, Armistead I, Yousey-Hindes K, Anderson EJ, Weigel A, Reeg L, Mumm E, Ropp SL, Muse AG, Bushey S, Shiltz E, Sutton M, Talbot K, Price A, Havers FP. 303. Viral and bacterial infections among adults hospitalized with COVID-19, Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, 14 states, March 2020–February 2022. Open Forum Infect Dis 2022. [PMCID: PMC9751616 DOI: 10.1093/ofid/ofac492.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background Coinfections, both bacterial and viral, occur with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood. Methods We used the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance platform to investigate the occurrence of viral and bacterial coinfections among hospitalized adults with laboratory-confirmed SARS-CoV-2 infection during March 2020 and February 2022. Patients receiving additional standard of care (SOC) molecular testing for viral pathogens (14 days prior to admission or 7 days after), including respiratory syncytial virus, rhinovirus/enterovirus (RV/EV), influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and endemic coronaviruses, were included. SOC testing for clinically relevant bacterial pathogens (7 days before admission or 7 days after) from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. Results Among 2,654 adults hospitalized with COVID-19 and tested for all 7 virus groups, another virus was identified in 3.1% of patients. RV/EV (1.2%) and influenza (0.4%) were the most commonly detected viruses. Half (17,842/35,528, 50.2%) of hospitalized adults with COVID-19 had bacterial cultures taken within 7 days of admission, and 1,092 (6.1%) of these had a clinically relevant bacterial pathogen. A higher percentage of those with a positive culture died compared to those with negative cultures (32.3% vs 13.3%, p< 0.001). Staphylococcus aureus was the most common isolate overall; Pseudomonas aeruginosa was the second most common respiratory isolate (Figure 1).
Microbial cultures from hospitalized sampled adults with COVID-19 from Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET) from March 2020 to February 2022 with bacterial pathogens detected in sputum, deep respiratory, or blood cultures within 7 days of admission. ![]() This figure includes 1,408 bacterial cultures from 1,066 individuals. Deep respiratory sites include endotracheal aspirate, bronchoalveolar lavage fluid, bronchial washings, pleural fluid, and lung tissue. Commensal organisms were excluded. Conclusion Consistent with previous studies, a relatively low proportion of adults hospitalized with COVID-19 had concomitantly identified viral or bacterial infections. Identification of a bacterial infection within 7 days of admission is associated with increased mortality among adults hospitalized with COVID-19. Conclusions about the clinical relevance of bacterial infections is limited by the retrospective nature of this study. Disclosures Evan J. Anderson, MD, GSK: Advisor/Consultant|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Kentucky Bioprocessing, Inc: Data Safety Monitoring Board|MedImmune: Grant/Research Support|Medscape: Advisor/Consultant|Merck: Grant/Research Support|Micron: Grant/Research Support|NIH: Funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines|PaxVax: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Regeneron: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant|Sanofi Pasteur: Grant/Research Support|Sanofi Pasteur: Data Adjudication and Data Safety Monitoring Boards|WCG and ACI Clinical: Data Adjudication Board.
Collapse
Affiliation(s)
- Shah Melisa
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Kadam Patel
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | - Huong Pham
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | - Isaac Armistead
- Colorado Department of Public Health and Environment, Denver, Colorado
| | | | | | - Andy Weigel
- Iowa Department of Public Health, Des Moines, Iowa
| | - Libby Reeg
- Michigan Department of Health and Human Services, Lansing, Michigan
| | - Erica Mumm
- Minnesota Department of Health, Saint Paul, Minnesota
| | - Susan L Ropp
- New Mexico Department of Health, Santa Fe, New Mexico
| | - Alison G Muse
- New York State Department of Health, Albany, New York
| | - Sophrena Bushey
- University of Rochester School of Medicine and Dentistry, Rochester, New York
| | - Eli Shiltz
- Ohio Department of Health, Columbus, Ohio
| | | | - Keipp Talbot
- Vanderbilt University Medical Center, Nashville, Tennessee
| | | | | |
Collapse
|
10
|
Garg S, Cummings CN, Ujamaa D, Kirley PD, Alden NB, Correa M, Anderson EJ, Weigel A, Monroe M, Nunez VT, McMahon M, Ropp SL, Spina NL, Gaitan M, Shiltz E, Sutton M, Talbot K, Crossland M, Reed C. 1537. Influenza-Associated Hospitalization Rates and Proportion of Hospitalizations with Influenza and SARS-CoV-2 Coinfection, FluSurv-NET, October 1, 2021–April 23, 2022. Open Forum Infect Dis 2022. [PMCID: PMC9752151 DOI: 10.1093/ofid/ofac492.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background Influenza-associated hospitalization rates were low during the 2020–21 season. We describe influenza-associated hospitalization rates and prevalence of influenza and SARS-CoV-2 coinfection among patients hospitalized with influenza during 2021–22. Methods We used data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based surveillance system for laboratory-confirmed influenza-associated hospitalizations active from October—April of each year. We calculated cumulative and weekly hospitalization rates per 100,000 population and compared preliminary rates during 2021–22 with prior season rates (2010–11 through 2020–21). We determined the proportion of influenza-associated hospitalizations with SARS-CoV-2 coinfection during 2021–22. Results During October 1, 2021—April 23, 2022, 3,262 influenza-associated hospitalizations were reported to FluSurv-NET; the cumulative hospitalization rate of 11.1 was higher than 2011–12 and 2020–21 season rates, but lower than rates observed during all other seasons since 2010–11 (Figure 1A). After peaking in the week ending January 1, 2022 (MMWR week 52), weekly hospitalization rates declined until the week ending February 19, 2022 (MMWR week 7) when they began to rise modestly, similar to patterns observed during several prior seasons (Figure 1B). Among the 3,262 hospitalizations, 87 (2.7%) had SARS-CoV-2 coinfection; the prevalence by age group was as follows: 0–17 years 3.4%, 18–49 years 2.8%, 50–64 years 3.5%, 65–74 years 2.5%, ≥ 75 years 1.6%. Among the 3,262 influenza-associated hospitalizations, the prevalence of SARS-CoV-2 coinfection by month (October 2021–April 2022), respectively, was 11.4%, 2.5%, 2.6%, 8.9%, 3.4%, 0.8%, and 0.5%. Conclusion SARS-CoV-2 coinfection was uncommon among patients hospitalized with influenza during 2021–22. Likely due to ongoing COVID-19 mitigation measures, the influenza-associated hospitalization rate during 2021–22 was lower than rates observed in most seasons in the decade preceding the COVID-19 pandemic. A late rise in weekly influenza hospitalization rates in 2021–22 might have been a result of relaxation of COVID-19 mitigation measures and/or a late season peak in influenza activity. Disclosures Evan J. Anderson, MD, GSK: Advisor/Consultant|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Kentucky Bioprocessing, Inc: Data Safety Monitoring Board|MedImmune: Grant/Research Support|Medscape: Advisor/Consultant|Merck: Grant/Research Support|Micron: Grant/Research Support|NIH: Funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines|PaxVax: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Regeneron: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant|Sanofi Pasteur: Grant/Research Support|Sanofi Pasteur: Data Adjudication and Data Safety Monitoring Boards|WCG and ACI Clinical: Data Adjudication Board Maya Monroe, MPH, CDC -Emerging Infections Program: Grant/Research Support.
Collapse
Affiliation(s)
- Shikha Garg
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Dawud Ujamaa
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Nisha B Alden
- Colorado Department of Public Health and Environment, Denver, Colorado
| | - Maria Correa
- Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut
| | | | - Andy Weigel
- Iowa Department of Public Health, Des Moines, Iowa
| | - Maya Monroe
- Maryland Department of Health, Baltimore, Maryland
| | - Val Tellez Nunez
- Michigan Department of Health and Human Services, Lansing, Michigan
| | | | - Susan L Ropp
- New Mexico Department of Health, Santa Fe, New Mexico
| | - Nancy L Spina
- New York State Department of Health, Albany, New York
| | - Maria Gaitan
- Rochester Emerging Infections Program, University of Rochester Medical Center, Rochester, New York
| | - Eli Shiltz
- Ohio Department of Health, Columbus, Ohio
| | | | - Keipp Talbot
- Vanderbilt University Medical Center, Nashville, Tennessee
| | | | | |
Collapse
|
11
|
Hamid S, Woodworth K, Pham H, Milucky J, Chai SJ, Kawasaki B, Yousey-Hindes K, Anderson EJ, Henderson J, Lynfield R, Pacheco F, Barney G, Bennett NM, Shiltz E, Sutton M, Talbot HK, Price A, Havers FP, Taylor CA. COVID-19-Associated Hospitalizations Among U.S. Infants Aged <6 Months - COVID-NET, 13 States, June 2021-August 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1442-1448. [PMID: 36355608 PMCID: PMC9707352 DOI: 10.15585/mmwr.mm7145a3] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/20/2023]
Abstract
COVID-19-associated hospitalization rates are highest among adults aged ≥65 years (1); however, COVID-19 can and does cause severe and fatal outcomes in children, including infants (2,3). After the emergence of the SARS-CoV-2 B.1.1.529 (Omicron) BA.1 variant in December 2021, hospitalizations among children aged <5 years, who were ineligible for vaccination, increased more rapidly than did those in other age groups (4). On June 18, 2022, CDC recommended COVID-19 vaccination for infants and children aged ≥6 months (5). Data from the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET)* were analyzed to describe changes in the age distribution of COVID-19-associated hospitalizations since the Delta-predominant period (June 20-December 18, 2021)† with a focus on U.S. infants aged <6 months. During the Omicron BA.2/BA.5-predominant periods (December 19, 2021–August 31, 2022), weekly hospitalizations per 100,000 infants aged <6 months increased from a nadir of 2.2 (week ending April 9, 2022) to a peak of 26.0 (week ending July 23, 2022), and the average weekly hospitalization rate among these infants (13.7) was similar to that among adults aged 65-74 years (13.8). However, the prevalence of indicators of severe disease§ among hospitalized infants did not increase since the B.1.617.2 (Delta)-predominant period. To help protect infants too young to be vaccinated, prevention should focus on nonpharmaceutical interventions and vaccination of pregnant women, which might provide protection through transplacental transfer of antibodies (6).
Collapse
|
12
|
Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, Kambhampati AK, Milucky J, Zell E, Moline HL, Chai SJ, Kirley PD, Alden NB, Armistead I, Yousey-Hindes K, Meek J, Openo KP, Anderson EJ, Reeg L, Kohrman A, Lynfield R, Como-Sabetti K, Davis EM, Cline C, Muse A, Barney G, Bushey S, Felsen CB, Billing LM, Shiltz E, Sutton M, Abdullah N, Talbot HK, Schaffner W, Hill M, George A, Hall AJ, Bialek SR, Murthy NC, Murthy BP, McMorrow M. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. JAMA Intern Med 2022; 182:1071-1081. [PMID: 36074486 PMCID: PMC9459904 DOI: 10.1001/jamainternmed.2022.4299] [Citation(s) in RCA: 67] [Impact Index Per Article: 33.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 08/04/2022] [Indexed: 12/24/2022]
Abstract
Importance Understanding risk factors for hospitalization in vaccinated persons and the association of COVID-19 vaccines with hospitalization rates is critical for public health efforts to control COVID-19. Objective To determine characteristics of COVID-19-associated hospitalizations among vaccinated persons and comparative hospitalization rates in unvaccinated and vaccinated persons. Design, Setting, and Participants From January 1, 2021, to April 30, 2022, patients 18 years or older with laboratory-confirmed SARS-CoV-2 infection were identified from more than 250 hospitals in the population-based COVID-19-Associated Hospitalization Surveillance Network. State immunization information system data were linked to cases, and the vaccination coverage data of the defined catchment population were used to compare hospitalization rates in unvaccinated and vaccinated individuals. Vaccinated and unvaccinated patient characteristics were compared in a representative sample with detailed medical record review; unweighted case counts and weighted percentages were calculated. Exposures Laboratory-confirmed COVID-19-associated hospitalization, defined as a positive SARS-CoV-2 test result within 14 days before or during hospitalization. Main Outcomes and Measures COVID-19-associated hospitalization rates among vaccinated vs unvaccinated persons and factors associated with COVID-19-associated hospitalization in vaccinated persons were assessed. Results Using representative data from 192 509 hospitalizations (see Table 1 for demographic information), monthly COVID-19-associated hospitalization rates ranged from 3.5 times to 17.7 times higher in unvaccinated persons than vaccinated persons regardless of booster dose status. From January to April 2022, when the Omicron variant was predominant, hospitalization rates were 10.5 times higher in unvaccinated persons and 2.5 times higher in vaccinated persons with no booster dose, respectively, compared with those who had received a booster dose. Among sampled cases, vaccinated hospitalized patients with COVID-19 were older than those who were unvaccinated (median [IQR] age, 70 [58-80] years vs 58 [46-70] years, respectively; P < .001) and more likely to have 3 or more underlying medical conditions (1926 [77.8%] vs 4124 [51.6%], respectively; P < .001). Conclusions and Relevance In this cross-sectional study of US adults hospitalized with COVID-19, unvaccinated adults were more likely to be hospitalized compared with vaccinated adults; hospitalization rates were lowest in those who had received a booster dose. Hospitalized vaccinated persons were older and more likely to have 3 or more underlying medical conditions and be long-term care facility residents compared with hospitalized unvaccinated persons. The study results suggest that clinicians and public health practitioners should continue to promote vaccination with all recommended doses for eligible persons.
Collapse
Affiliation(s)
- Fiona P Havers
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- Public Health Service Commissioned Corps, Rockville, Maryland
| | - Huong Pham
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
| | - Christopher A Taylor
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
| | - Michael Whitaker
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
| | - Kadam Patel
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- General Dynamics Information Technology, Atlanta, Georgia
| | - Onika Anglin
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- General Dynamics Information Technology, Atlanta, Georgia
| | - Anita K Kambhampati
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
| | - Jennifer Milucky
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
| | - Elizabeth Zell
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- Stat-Epi Associates, Inc, Ponte Vedra Beach, Florida
| | - Heidi L Moline
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- Public Health Service Commissioned Corps, Rockville, Maryland
| | - Shua J Chai
- Field Services Branch, Division of State and Local Readiness, Center for Preparedness and Response, US Centers for Disease Control and Prevention, Atlanta, Georgia
- California Emerging Infections Program, Oakland
| | | | - Nisha B Alden
- Colorado Department of Public Health and Environment, Denver
| | - Isaac Armistead
- Colorado Department of Public Health and Environment, Denver
| | | | - James Meek
- Connecticut Emerging Infections Program, Yale School of Public Health, New Haven
| | - Kyle P Openo
- Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia
- Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta
| | - Evan J Anderson
- Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta
- Departments of Medicine and Pediatrics, Emory School of Medicine, Atlanta, Georgia
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia
| | - Libby Reeg
- Michigan Department of Health and Human Services, Lansing
| | | | | | | | | | - Cory Cline
- New Mexico Department of Health, Santa Fe
| | | | | | - Sophrena Bushey
- University of Rochester School of Medicine and Dentistry, Rochester, New York
| | - Christina B Felsen
- University of Rochester School of Medicine and Dentistry, Rochester, New York
| | | | | | - Melissa Sutton
- Public Health Division, Oregon Health Authority, Portland
| | | | - H Keipp Talbot
- Vanderbilt University Medical Center, Nashville, Tennessee
| | | | - Mary Hill
- Salt Lake County Health Department, Salt Lake City, Utah
| | - Andrea George
- Salt Lake County Health Department, Salt Lake City, Utah
| | - Aron J Hall
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
| | - Stephanie R Bialek
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- Public Health Service Commissioned Corps, Rockville, Maryland
| | - Neil C Murthy
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- Public Health Service Commissioned Corps, Rockville, Maryland
| | - Bhavini Patel Murthy
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- Public Health Service Commissioned Corps, Rockville, Maryland
| | - Meredith McMorrow
- US Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia
- Public Health Service Commissioned Corps, Rockville, Maryland
| |
Collapse
|
13
|
Marks KJ, Whitaker M, Agathis NT, Anglin O, Milucky J, Patel K, Pham H, Kirley PD, Kawasaki B, Meek J, Anderson EJ, Weigel A, Kim S, Lynfield R, Ropp SL, Spina NL, Bennett NM, Shiltz E, Sutton M, Talbot HK, Price A, Taylor CA, Havers FP. Hospitalization of Infants and Children Aged 0-4 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:429-436. [PMID: 35298458 PMCID: PMC8942304 DOI: 10.15585/mmwr.mm7111e2] [Citation(s) in RCA: 104] [Impact Index Per Article: 52.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
14
|
Marks KJ, Whitaker M, Anglin O, Milucky J, Patel K, Pham H, Chai SJ, Kirley PD, Armistead I, McLafferty S, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Weigel A, Henderson J, Nunez VT, Como-Sabetti K, Lynfield R, Ropp SL, Smelser C, Barney GR, Muse A, Bennett NM, Bushey S, Billing LM, Shiltz E, Abdullah N, Sutton M, Schaffner W, Talbot HK, Chatelain R, George A, Taylor CA, McMorrow ML, Perrine CG, Havers FP. Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:271-278. [PMID: 35176003 PMCID: PMC8853476 DOI: 10.15585/mmwr.mm7107e4] [Citation(s) in RCA: 105] [Impact Index Per Article: 52.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
15
|
Taylor CA, Patel K, Pham H, Whitaker M, Anglin O, Kambhampati AK, Milucky J, Chai SJ, Kirley PD, Alden NB, Armistead I, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Teno K, Weigel A, Monroe ML, Ryan PA, Henderson J, Nunez VT, Bye E, Lynfield R, Poblete M, Smelser C, Barney GR, Spina NL, Bennett NM, Popham K, Billing LM, Shiltz E, Abdullah N, Sutton M, Schaffner W, Talbot HK, Ortega J, Price A, Garg S, Havers FP. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1513-1519. [PMID: 34710076 PMCID: PMC8553023 DOI: 10.15585/mmwr.mm7043e1] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Acosta AM, Garg S, Pham H, Whitaker M, Anglin O, O’Halloran A, Milucky J, Patel K, Taylor C, Wortham J, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Reeg L, Kohrman A, Lynfield R, Bye E, Torres S, Salazar-Sanchez Y, Muse A, Barney G, Bennett NM, Bushey S, Billing L, Shiltz E, Sutton M, Abdullah N, Talbot HK, Schaffner W, Ortega J, Price A, Fry AM, Hall A, Kim L, Havers FP. Racial and Ethnic Disparities in Rates of COVID-19-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021. JAMA Netw Open 2021; 4:e2130479. [PMID: 34673962 PMCID: PMC8531997 DOI: 10.1001/jamanetworkopen.2021.30479] [Citation(s) in RCA: 134] [Impact Index Per Article: 44.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
IMPORTANCE Racial and ethnic minority groups are disproportionately affected by COVID-19. OBJECTIVES To evaluate whether rates of severe COVID-19, defined as hospitalization, intensive care unit (ICU) admission, or in-hospital death, are higher among racial and ethnic minority groups compared with non-Hispanic White persons. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study included 99 counties within 14 US states participating in the COVID-19-Associated Hospitalization Surveillance Network. Participants were persons of all ages hospitalized with COVID-19 from March 1, 2020, to February 28, 2021. EXPOSURES Laboratory-confirmed COVID-19-associated hospitalization, defined as a positive SARS-CoV-2 test within 14 days prior to or during hospitalization. MAIN OUTCOMES AND MEASURES Cumulative age-adjusted rates (per 100 000 population) of hospitalization, ICU admission, and death by race and ethnicity. Rate ratios (RR) were calculated for each racial and ethnic group compared with White persons. RESULTS Among 153 692 patients with COVID-19-associated hospitalizations, 143 342 (93.3%) with information on race and ethnicity were included in the analysis. Of these, 105 421 (73.5%) were 50 years or older, 72 159 (50.3%) were male, 28 762 (20.1%) were Hispanic or Latino, 2056 (1.4%) were non-Hispanic American Indian or Alaska Native, 7737 (5.4%) were non-Hispanic Asian or Pacific Islander, 40 806 (28.5%) were non-Hispanic Black, and 63 981 (44.6%) were White. Compared with White persons, American Indian or Alaska Native, Latino, Black, and Asian or Pacific Islander persons were more likely to have higher cumulative age-adjusted rates of hospitalization, ICU admission, and death as follows: American Indian or Alaska Native (hospitalization: RR, 3.70; 95% CI, 3.54-3.87; ICU admission: RR, 6.49; 95% CI, 6.01-7.01; death: RR, 7.19; 95% CI, 6.47-7.99); Latino (hospitalization: RR, 3.06; 95% CI, 3.01-3.10; ICU admission: RR, 4.20; 95% CI, 4.08-4.33; death: RR, 3.85; 95% CI, 3.68-4.01); Black (hospitalization: RR, 2.85; 95% CI, 2.81-2.89; ICU admission: RR, 3.17; 95% CI, 3.09-3.26; death: RR, 2.58; 95% CI, 2.48-2.69); and Asian or Pacific Islander (hospitalization: RR, 1.03; 95% CI, 1.01-1.06; ICU admission: RR, 1.91; 95% CI, 1.83-1.98; death: RR, 1.64; 95% CI, 1.55-1.74). CONCLUSIONS AND RELEVANCE In this cross-sectional analysis, American Indian or Alaska Native, Latino, Black, and Asian or Pacific Islander persons were more likely than White persons to have a COVID-19-associated hospitalization, ICU admission, or in-hospital death during the first year of the US COVID-19 pandemic. Equitable access to COVID-19 preventive measures, including vaccination, is needed to minimize the gap in racial and ethnic disparities of severe COVID-19.
Collapse
Affiliation(s)
- Anna M. Acosta
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Shikha Garg
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
- US Public Health Service, Rockville, Maryland
| | - Huong Pham
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Michael Whitaker
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Onika Anglin
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
- General Dynamics Information Technology, Atlanta, Georgia
| | - Alissa O’Halloran
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Jennifer Milucky
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Kadam Patel
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
- General Dynamics Information Technology, Atlanta, Georgia
| | - Christopher Taylor
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Jonathan Wortham
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
- US Public Health Service, Rockville, Maryland
| | - Shua J. Chai
- California Emerging Infections Program, Oakland
- Career Epidemiology Field Officer, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Nisha B. Alden
- Colorado Department of Public Health and Environment, Denver
| | | | - James Meek
- Connecticut Emerging Infections Program, Yale School of Public Health, New Haven
| | | | - Evan J. Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
- Georgia Emerging Infections Program, Georgia Department of Health, Atlanta
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia
| | - Kyle P. Openo
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
- Georgia Emerging Infections Program, Georgia Department of Health, Atlanta
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia
| | | | | | | | - Libby Reeg
- Michigan Department of Health and Human Services, Lansing
| | | | | | - Erica Bye
- Minnesota Department of Health, St Paul
| | | | | | | | | | - Nancy M. Bennett
- University of Rochester School of Medicine and Dentistry, Rochester, New York
| | - Sophrena Bushey
- University of Rochester School of Medicine and Dentistry, Rochester, New York
| | | | | | | | | | - H. Keipp Talbot
- Vanderbilt University School of Medicine, Nashville, Tennessee
| | | | - Jake Ortega
- Salt Lake County Health Department, Salt Lake City, Utah
| | - Andrea Price
- Salt Lake County Health Department, Salt Lake City, Utah
| | - Alicia M. Fry
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
- US Public Health Service, Rockville, Maryland
| | - Aron Hall
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Lindsay Kim
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
- US Public Health Service, Rockville, Maryland
| | - Fiona P. Havers
- COVID-19-Associated Hospitalization Surveillance Network, US Centers for Disease Control and Prevention, Atlanta, Georgia
- US Public Health Service, Rockville, Maryland
| |
Collapse
|
17
|
Delahoy MJ, Ujamaa D, Whitaker M, O'Halloran A, Anglin O, Burns E, Cummings C, Holstein R, Kambhampati AK, Milucky J, Patel K, Pham H, Taylor CA, Chai SJ, Reingold A, Alden NB, Kawasaki B, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Teno K, Weigel A, Kim S, Leegwater L, Bye E, Como-Sabetti K, Ropp S, Rudin D, Muse A, Spina N, Bennett NM, Popham K, Billing LM, Shiltz E, Sutton M, Thomas A, Schaffner W, Talbot HK, Crossland MT, McCaffrey K, Hall AJ, Fry AM, McMorrow M, Reed C, Garg S, Havers FP. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1255-1260. [PMID: 34499627 PMCID: PMC8437052 DOI: 10.15585/mmwr.mm7036e2] [Citation(s) in RCA: 196] [Impact Index Per Article: 65.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|